Hologic Inc
NASDAQ:HOLX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (3.6), the stock would be worth $83.51 (10% upside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 3.2 | $76.01 |
0%
|
| 3-Year Average | 3.6 | $83.51 |
+10%
|
| 5-Year Average | 3.7 | $86.37 |
+14%
|
| Industry Average | 3.1 | $73.4 |
-3%
|
| Country Average | 2.5 | $59.11 |
-22%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Hologic Inc
NASDAQ:HOLX
|
17B USD | 3.2 | 31.2 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
171.2B USD | 9.6 | 60 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
158.3B USD | 3 | 25.2 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.3B USD | 5.6 | 38.6 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.9B USD | 2.2 | 23.2 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
92B USD | 3.8 | 25.8 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
40B EUR | 2.2 | 18.9 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.9B USD | 4.7 | 44.6 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.1B USD | 28.1 | 42.6 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
43.3B USD | 1.7 | 24.7 | |
| US |
|
Resmed Inc
NYSE:RMD
|
32B USD | 5.1 | 21.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.5 |
| Median | 2.5 |
| 70th Percentile | 4.8 |
| Max | 147 580.5 |
Other Multiples
Hologic Inc
Glance View
Hologic Inc., headquartered in Marlborough, Massachusetts, crafts a narrative deeply intertwined with the vital mission of women's health. Established in 1985, the company has grown into a prominent player in the medical device and diagnostics realm. Hologic’s success is anchored in its core business sectors: Breast & Skeletal Health, Diagnostic Solutions, GYN Surgical, and Medical Aesthetics. The cornerstone of this expansive operation is innovation, driving the development of advanced technologies like 3D mammography systems that revolutionize breast cancer detection. This strategic focus on high-value diagnostics and medical equipment allows Hologic to capture significant market share, ensuring a steady revenue stream from both capital equipment sales and ongoing service and maintenance contracts. Beyond its robust presence in imaging and diagnostics, Hologic amplifies its influence through a comprehensive array of solutions for early stage disease detection and treatment. Their Diagnostic Solutions arm, particularly strengthened by molecular diagnostic tests, is a response to the increasing global demand for rapid and accurate testing solutions—a need only intensified by recent global health challenges. These products not only provide critical tools for healthcare professionals but also secure recurring income for Hologic through the sale of consumables and tests. By embedding itself in the cycles of medical advancements and enhancing the standard of care, Hologic generates sustainable growth and remains a crucial ally in both public and specialized health sectors. The company’s blend of technology-driven products and strategic agility enables it to navigate dynamic markets while maintaining a resolute focus on improving health outcomes around the world.